// App-Quantinova.ai

1648 : Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database

Researchers

Presenter

  • Eiichi Tanaka

Principal Investigators

  • Ryoko Sakai

  • Eisuke Inoue

  • Masayoshi Harigai

Medical Centers

  • Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

  • Meiji Pharmaceutical Univ., Tokyo, Japan

  • Research Administration Center, Showa University, Shinagawa-ku, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Myocardial infarction

  • Rheumatoid arthritis

  • Venous thrombosis

  • Inflammatory Arthritis

  • Stroke

Biomarkers

  • Interleukin 6

Drug/Treatment

  • ABT-494

  • Baricitinib

  • Tasocitinib

  • Peficitinib

  • Filgotinib

  • Abatacept

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved